Ironwood Pharmaceuticals Inc (IRWD)

15.72
NASDAQ : Health Care
Prev Close 15.87
Day Low/High 15.70 / 15.99
52 Wk Low/High 7.35 / 16.11
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 145.32M
Market Cap 2.31B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock

Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a weak on high relative volume candidate

Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its second quarter 2016 results and recent business activities.

Synergy Pharma Offers Lots of Synergies

Synergy Pharma Offers Lots of Synergies

I expect Allergan or another player to bid for SGYP soon.

Ironwood Pharmaceuticals To Host Second Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2016 investor update conference call and webcast at 4:30 p.

3 Stocks Pushing The Health Services Industry Higher

3 Stocks Pushing The Health Services Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Strong On High Relative Volume: Ironwood Pharmaceuticals (IRWD)

Strong On High Relative Volume: Ironwood Pharmaceuticals (IRWD)

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Insider Trading Alert - WTS, IRWD And SALM Traded By Insiders

Insider Trading Alert - WTS, IRWD And SALM Traded By Insiders

Stocks with insider trader activity include WTS, IRWD and SALM

Ironwood Pharmaceuticals To Present At Jefferies 2016 Healthcare Conference

Ironwood Pharmaceuticals To Present At Jefferies 2016 Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies 2016 Healthcare Conference on Friday, June 10, 2016 at 2:30 p.

Ironwood Pharmaceuticals Closes U.S. Transaction With AstraZeneca For Lesinurad

Ironwood Pharmaceuticals Closes U.S. Transaction With AstraZeneca For Lesinurad

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that it has closed the previously-announced transaction with AstraZeneca for the exclusive U.

Ironwood Pharmaceuticals To Present At Goldman Sachs 37th Annual Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Goldman Sachs 37th Annual Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 37 th Annual Global Healthcare Conference on Tuesday, June 7, 2016 at 4:00 p.

IRWD July 15th Options Begin Trading

IRWD July 15th Options Begin Trading

Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading today, for the July 15th expiration.

Ironwood Pharmaceuticals To Present At 2016 UBS Global Healthcare Conference

Ironwood Pharmaceuticals To Present At 2016 UBS Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2016 UBS Global Healthcare Conference on Wednesday, May 25, 2016 at 9:00 a.

Ironwood Pharmaceuticals To Present Linaclotide Data At Digestive Disease Week® 2016

Ironwood Pharmaceuticals To Present Linaclotide Data At Digestive Disease Week® 2016

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the presentation of linaclotide-related clinical and preclinical data from the company and its collaborators during Digestive Disease Week® (DDW)...

Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update

Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its first quarter 2016 results and recent business activities.

Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

Ironwood Pharmaceuticals To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 3:40 p.

Today's Dead Cat Bounce Stock: Ironwood Pharmaceuticals (IRWD)

Today's Dead Cat Bounce Stock: Ironwood Pharmaceuticals (IRWD)

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a "dead cat bounce" (down big yesterday but up big today) candidate

Ironwood Pharmaceuticals Enters Into U.S. Licensing Agreement With AstraZeneca For Lesinurad

Ironwood Pharmaceuticals Enters Into U.S. Licensing Agreement With AstraZeneca For Lesinurad

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that it has entered into a licensing agreement with AstraZeneca plc for the exclusive U.

Ironwood Pharmaceuticals To Host First Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals To Host First Quarter 2016 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2016 investor update conference call and webcast at 4:30 p.

Synergy Pharmaceuticals Soars After FDA Filing Accepted

Synergy Pharmaceuticals Soars After FDA Filing Accepted

Biotech company Synergy was rising by 9% on Tuesday. But is it a buy?

Ironwood Pharmaceuticals Appoints Andrew Dreyfus To Board Of Directors

Ironwood Pharmaceuticals Appoints Andrew Dreyfus To Board Of Directors

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the appointment of Andrew Dreyfus, president and chief executive officer of Blue Cross Blue Shield of Massachusetts, to its board of directors.

Ironwood Pharmaceuticals Reports Top-Line Data From Exploratory Phase IIa Study Of IW-9179 In Diabetic Gastroparesis

Ironwood Pharmaceuticals Reports Top-Line Data From Exploratory Phase IIa Study Of IW-9179 In Diabetic Gastroparesis

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that top-line data from an exploratory Phase IIa clinical study indicate IW-9179 did not meaningfully reduce the severity of symptoms in patients with...

Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Volume Stock

Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Ironwood Pharmaceuticals To Present Clinical And Preclinical Data On SGC Stimulators At Upcoming Scientific Conferences

Ironwood Pharmaceuticals To Present Clinical And Preclinical Data On SGC Stimulators At Upcoming Scientific Conferences

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the company and its academic collaborators will present clinical and preclinical data on several soluble guanylate cyclase (sGC) stimulators from...

Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that it initiated a Phase IIb clinical trial of IW-3718 in patients with refractory gastroesophageal reflux disease (GERD).

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Barclays Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016 at 11:15 a.